Martin S Tallman

List of Publications by Year
in descending order

211 papers	12,884 citations	53660 45 h-index	25716 108 g-index
214 all docs	214 docs citations	214 times ranked	14610 citing authors

#	Article	IF	Citations
1	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	0.6	4,375
2	Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML. New England Journal of Medicine, 2018, 378, 2386-2398.	13.9	1,092
3	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	5.2	578
4	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
5	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood, 2017, 130, 732-741.	0.6	300
6	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326.	13.9	257
7	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	2.9	237
8	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature, 2018, 559, 125-129.	13.7	223
9	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	7.7	220
10	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	15.2	195
11	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	0.6	193
12	Emerging therapeutic drugs for AML. Blood, 2016, 127, 71-78.	0.6	168
13	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia, 2019, 33, 2575-2584.	3.3	164
14	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances, 2016, 1, 250-259.	2.5	142
15	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	7.7	138
16	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	0.6	127
17	Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Advances, 2020, 4, 5966-5975.	2.5	124
18	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 137, 1792-1803.	0.6	123

#	Article	IF	Citations
19	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	7.7	118
20	Molecular therapy for acute myeloid leukaemia. Nature Reviews Clinical Oncology, 2016, 13, 305-318.	12.5	111
21	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	0.6	110
22	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 2016, 127, 1551-1558.	0.6	105
23	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). Blood, 2015, 126, 6-6.	0.6	104
24	Hematopoietic Stem Cell Origin of BRAF V600E Mutations in Hairy Cell Leukemia. Science Translational Medicine, 2014, 6, 238ra71.	5.8	102
25	Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances, 2021, 5, 1552-1564.	2.5	102
26	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. Journal of Clinical Oncology, 2016, 34, 3544-3553.	0.8	99
27	Differentiation syndrome in acute promyelocytic leukaemia. British Journal of Haematology, 2019, 187, 157-162.	1.2	88
28	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	0.6	78
29	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
30	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics, 2017, 49, 866-875.	9.4	75
31	A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia. PLoS ONE, 2014, 9, e108694.	1.1	72
32	Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329.	2.0	72
33	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	2.5	71
34	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematology,the, 2020, 7, e309-e319.	2.2	70
35	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	0.6	64
36	How I treat relapsed or refractory AML. Blood, 2020, 136, 1023-1032.	0.6	64

#	Article	IF	Citations
37	Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1021-1025.	2.0	61
38	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	0.8	61
39	MEF2C Phosphorylation Is Required forÂChemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2018, 8, 478-497.	7.7	59
40	Molecular classification improves risk assessment in adult BCR-ABL1â€“negative B-ALL. Blood, 2021, 138, 948-958.	0.6	59
41	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 1252-1257.	0.8	57
42	Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia and Lymphoma, 2019, 60, 3107-3115.	0.6	56
43	Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia Research, 2019, 79, 27-33.	0.4	54
44	Time to repeal and replace response criteria for acute myeloid leukemia?. Blood Reviews, 2018, 32, 416-425.	2.8	51
45	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	3.3	51
46	A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood, 2018, 132, LBA-4-LBA-4.	0.6	48
47	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1071-1071.	0.6	47
48	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood, 2016, 128, 763-773.	0.6	46
49	A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Medicine, 2016, 5, 3031-3040.	1.3	46
50	How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood, 2016, 128, 488-496.	0.6	45
51	Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals of Hematology, 2022, 101, 557-569.	0.8	44
52	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. Blood, 2015, 126, 2547-2547.	0.6	42
53	Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. International Journal of Hematology, 2013, 97, 456-464.	0.7	37
54	Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML). Blood, 2013, 122, 494-494.	0.6	36

#	Article	IF	Citations
55	Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. Blood, 2015, 126, 1306-1306.	0.6	36
56	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). Blood, 2013, 122, 3903-3903.	0.6	35
57	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood, 2010, 116, 5650-5659.	0.6	33
58	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
59	Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study. Journal of Infection, 2018, 77, 227-234.	1.7	31
60	The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia. Seminars in Thrombosis and Hemostasis, 2019, 45, 612-621.	1.5	31
61	Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica, 2016, 101, e457-e460.	1.7	30
62	Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leukemia Research, 2018, 66, 49-56.	0.4	29
63	TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia. Blood, 2018, 132, 1433-1433.	0.6	29
64	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	3.3	28
65	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 2021, 35, 1864-1872.	3.3	28
66	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 580-597.	0.2	28
67	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	3.9	28
68	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age â‰¥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood, 2015, 126, 217-217.	0.6	28
69	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. Blood, 2016, 128, 1070-1070.	0.6	28
70	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematology,the, 2021, 8, e922-e933.	2.2	27
71	Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British Journal of Haematology, 2016, 175, 402-409.	1.2	26
72	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research, 2020, 95, 106385.	0.4	26

#	Article	IF	Citations
73	Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Leukemia and Lymphoma, 2011, 52, 65-68.	0.6	25
74	Aberrant GSK3Î² nuclear localization promotes AML growth and drug resistance. Blood Advances, 2018, 2, 2890-2903.	2.5	25
75	Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. Cancer Discovery, 2020, 10, 1500-1513.	7.7	24
76	Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica, 2021, 106, 2086-2094.	1.7	24
77	Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations forÂNew Diagnostic Criteria. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 146-151.	0.2	22
78	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 1078-1086.	2.0	22
79	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of Clinical Oncology, 2021, 39, 1001-1009.	0.8	22
80	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leukemia Research, 2014, 38, 329-333.	0.4	21
81	Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial. Blood, 2017, 130, 726-726.	0.6	20
82	The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leukemia Research, 2016, 50, 17-20.	0.4	18
83	Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica, 2018, 103, e5-e9.	1.7	18
84	Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia Research, 2016, 49, 62-65.	0.4	17
85	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leukemia Research, 2017, 59, 55-64.	0.4	17
86	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 3394-3401.	0.6	17
87	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 771.e1-771.e10.	0.6	17
88	Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1879-1886.	2.0	16
89	Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thrombosis Research, 2018, 164, S98-S102.	0.8	16
90	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica, 2020, 105, 161-169.	1.7	15

#	Article	IF	Citations
91	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research, 2020, 93, 106367.	0.4	15
92	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood, 2015, 126, 2546-2546.	0.6	15
93	Melanoma and nonâ€melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30â€year experience at Memorial Sloan Kettering Cancer Center. British Journal of Haematology, 2015, 171, 84-90.	1.2	14
94	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for I nternational B lood and M arrow T ransplant R esearch cohort analysis. Cancer, 2017, 123, 2035-2042.	2.0	14
95	Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. Journal of Clinical Oncology, 2021, 39, 2535-2538.	0.8	14
96	Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia. Blood, 2013, 122, 623-623.	0.6	14
97	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. Blood, 2017, 130, 725-725.	0.6	14
98	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	0.6	14
99	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
100	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOGâ€ACRIN cancer research group (E1908). American Journal of Hematology, 2016, 91, 308-312.	2.0	13
101	Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e566-e574.	2.2	13
102	Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health. Blood, 2016, 128, 223-223.	0.6	13
103	Multicenter evaluation of efficacy and toxicity of venetoclaxâ€based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, .	2.0	13
104	Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Cancer Discovery, 2022, 12, 856-871.	7.7	13
105	Hairy cell leukemia: Past, present and future. Best Practice and Research in Clinical Haematology, 2015, 28, 269-272.	0.7	12
106	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. Blood, 2015, 126, 796-796.	0.6	12
107	Don't just stand there, do something: Strategies for the prevention of early death in acute promyelocytic leukemia: A commentary. Blood Cells, Molecules, and Diseases, 2011, 46, 173-174.	0.6	11
108	Younger adults with acute myeloid leukemia in remission for â‰¥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leukemia Research, 2014, 38, 901-906.	0.4	10

#	Article	IF	Citations
109	Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co-Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML. Blood, 2018, 132, 1436-1436.	0.6	10
110	ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial. Blood, 2016, 128, 896-896.	0.6	10
111	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica, 2022, 107, 770-773.	1.7	10
112	Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease. Journal of Hematology (Brossard, Quebec), 2020, 9, 18-22.	0.4	9
113	Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis. Blood, 2018, 132, 2789-2789.	0.6	8
114	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. Blood, 2011, 118, 289-289.	0.6	8
115	AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2015, 126, 4075-4075.	0.6	8
116	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American Journal of Hematology, 2016, 91, 1107-1112.	2.0	7
117	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.	2.0	7
118	Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 176-184.	0.6	7
119	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia and Lymphoma, 2021, 62, 1940-1948.	0.6	7
120	Widespread use of measurable residual disease in acute myeloid leukemia practice. Leukemia Research, 2018, 67, 92-98.	0.4	6
121	A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial. Blood, 2016, 128, 1629-1629.	0.6	6
122	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 581-586.	2.0	5
123	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
124	Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1414-1414.	0.6	5
125	Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 2741-2741.	0.6	5
126	Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy. Blood, 2018, 132, 665-665.	0.6	5

#	Article	IF	Citations
127	Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG. Blood, 2020, 136, 31-32.	0.6	5
128	Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis. Blood, 2020, 136, 34-35.	0.6	5
129	Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. Blood, 2013, 122, 2777-2777.	0.6	5
130	Novel therapeutic strategies for AML in 2012. Hematology, 2012, 17, s43-s46.	0.7	4
131	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica, 2019, 104, e147-e150.	1.7	4
132	A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN. Blood Advances, 2020, 4, 6034-6038.	2.5	4
133	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age â‰¥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. Blood, 2018, 132, 437-437.	0.6	4
134	Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2018, 132, 4013-4013.	0.6	4
135	High-Grade Pegylated Asparaginase-Related Hepatotoxicity Occurrence In a Pediatric-Inspired Adult Acute Lymphoblastic Leukemia Regimen Does Not Necessarily Predict Recurrent Hepatotoxicity In Subsequent Cycles. Blood, 2013, 122, 2671-2671.	0.6	4
136	Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia. Blood, 2013, 122, 2876-2876.	0.6	4
137	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.. Journal of Clinical Oncology, 2017, 35, 7016-7016.	0.8	4
138	Acute Leukemias Following a Diagnosis of Colorectal Cancer: Are They Therapy-Related?. Blood, 2012, 120, 1453-1453.	0.6	4
139	Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rÎ³null Mice for Preclinical Ceramide-Based Therapeutic Evaluation. Journal of Leukemia (Los Angeles, Calif), 2014, 02, .	0.1	3
140	Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors. Blood, 2018, 132, 87-87.	0.6	3
141	Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents. Blood, 2018, 132, 233-233.	0.6	3
142	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). Blood, 2018, 132, 435-435.	0.6	3
143	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age â‰¥60 Years. Blood, 2018, 132, 3995-3995.	0.6	3
144	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	0.6	3

#	Article	IF	Citations
145	Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3816-3816.	0.6	3
146	Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Blood, 2020, 136, 18-20.	0.6	3
147	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. Blood, 2015, 126, 4161-4161.	0.6	3
148	Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia. Blood, 2015, 126, 449-449.	0.6	3
149	TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 3481-3481.	0.6	3
150	Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia. Leukemia Research, 2018, 65, 80-85.	0.4	2
151	Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation. Blood Advances, 2018, 2, 1517-1521.	2.5	2
152	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). Leukemia Research, 2019, 78, 29-33.	0.4	2
153	Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)â€“associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients. Journal of the American Academy of Dermatology, 2021, , .	0.6	2
154	Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Leukemia Research, 2021, 106, 106569.	0.4	2
155	Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy. Blood, 2018, 132, 2668-2668.	0.6	2
156	AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival. Blood, 2018, 132, 1471-1471.	0.6	2
157	De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes. Blood, 2019, 134, 2708-2708.	0.6	2
158	Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan Kettering Cancer Center. Blood, 2015, 126, 1476-1476.	0.6	2
159	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2911-2911.	0.6	2
160	Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 834-834.	0.6	2
161	Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naÃ¯ve acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2497-2501.	0.6	1
162	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). Blood, 2018, 132, 1534-1534.	0.6	1

#	Article	IF	Citations
163	Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl. Blood, 2018, 132, 392-392.	0.6	1
164	Pharmacokinetics-Based Modification of Intravenous Pegylated Asparaginase Dosing in the Context of a â€œPediatric-inspiredâ€•Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 1495-1495.	0.6	1
165	Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). Blood, 2012, 120, 3624-3624.	0.6	1
166	BRAFV600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia. Blood, 2013, 122, 816-816.	0.6	1
167	Herpes Zoster Is More Frequent in Patients Receiving Higher Cumulative Doses of Arsenic Trioxide and Is Mitigated By Prophylactic Acyclovir. Blood, 2015, 126, 3752-3752.	0.6	1
168	A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).. Journal of Clinical Oncology, 2017, 35, 7503-7503.	0.8	1
169	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. Blood, 2015, 126, 172-172.	0.6	1
170	Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2018, 132, 292-292.	0.6	1
171	Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood, 2020, 136, 47-48.	0.6	1
172	Advances in the Treatment of Hairy Cell Leukemia Variant. Current Treatment Options in Oncology, 2022, 23, 99-116.	1.3	1
173	Acute Leukemias. Hematology/Oncology Clinics of North America, 2011, 25, xi-xii.	0.9	0
174	Treatment breakthroughs for the management of acute myeloid leukemia. International Journal of Hematologic Oncology, 2012, 1, 121-132.	0.7	0
175	The best of times in hematologic malignancies. Current Opinion in Hematology, 2015, 22, 75-76.	1.2	0
176	Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission. Leukemia and Lymphoma, 2018, 59, 269-271.	0.6	0
177	Choosing for whom to recommend allogeneic transplantation for acute myeloid leukemia in CR1: a continued, complicated conversation. Blood Advances, 2018, 2, 164-164.	2.5	0
178	Exciting Times in Acute Myeloid Leukemia. Seminars in Hematology, 2019, 56, 83.	1.8	0
179	Antibody-based therapy in acute leukemia - beware the risks. Leukemia and Lymphoma, 2019, 60, 1608-1609.	0.6	0
180	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia Research, 2019, 82, 19-23.	0.4	0

#	Article	IF	Citations
181	Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. Leukemia and Lymphoma, 2021, 62, 2050-2051.	0.6	0
182	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	0.6	0
183	Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts. Blood, 2011, 118, 942-942.	0.6	0
184	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. Blood, 2011, 118, 3619-3619.	0.6	0
185	Predicting Therapy-Related Acute Myeloid Leukemia By Routine Laboratory Values: An Analysis Of 126 Patients With Breast Cancer Referred For Bone Marrow Biopsy At Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 2661-2661.	0.6	0
186	A High Complete Remission Rate Can Be Achieved In Older Patients (Age â‰¥60) With Acute Lymphoblastic Leukemia Regardless Of Induction Intensities: Single-Institution Experience At Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 2638-2638.	0.6	0
187	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2013, 122, 2586-2586.	0.6	0
188	Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 5274-5274.	0.6	0
189	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. Blood, 2015, 126, 795-795.	0.6	0
190	Patient Characteristics and Early Death Predictors in Acute Promyelocytic Leukaemia Patients; Experience from United Arab Emirates (UAE). Blood, 2015, 126, 4963-4963.	0.6	0
191	A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Blood, 2015, 126, 64-64.	0.6	0
192	Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients. Blood, 2015, 126, 3810-3810.	0.6	0
193	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	0.6	0
194	Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway. Blood, 2015, 126, 2522-2522.	0.6	0
195	A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML. Blood, 2015, 126, 2591-2591.	0.6	0
196	Cytogenetics in Hairy Cell Leukemia at Diagnosis and Relapse: The Rate of Therapy-Related Myeloid Malignancies Is Low. Blood, 2015, 126, 2644-2644.	0.6	0
197	Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group. Blood, 2016, 128, 4373-4373.	0.6	0
198	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Patients with Myelodysplastic Syndromes. Blood, 2016, 128, 3188-3188.	0.6	0

#	Article	IF	Citations
199	A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986.	0.6	0
200	Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study. Blood, 2016, 128, 1650-1650.	0.6	0
201	Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program. Blood, 2016, 128, 4008-4008.	0.6	0
202	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. Blood, 2016, 128, 739-739.	0.6	0
203	Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia. Blood, 2018, 132, 1523-1523.	0.6	0
204	Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial. Blood, 2018, 132, 2692-2692.	0.6	0
205	PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes. Blood, 2018, 132, 2788-2788.	0.6	0
206	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0
207	Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1217-1217.	0.6	0
208	Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. Blood, 2018, 132, 1532-1532.	0.6	0
209	Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AMLâ€•A strong case for allogeneic stem cell transplantation in first complete remission. British Journal of Haematology, 2020, 189, 806-808.	1.2	0
210	Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. Blood, 2021, 138, 690-690.	0.6	0
211	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. Blood, 2020, 136, 16-17.	0.6	0